Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2008 1
2010 1
2011 1
2012 1
2013 2
2015 3
2018 2
2019 3
2020 2
2021 4
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2.
Nakanishi A, Okumura H, Hashita T, Yamashita A, Nishimura Y, Watanabe C, Kamimura S, Hayashi S, Murakami S, Ito K, Iwao T, Ikeda A, Hirose T, Sunazuka T, Tanaka Y, Matsunaga T. Nakanishi A, et al. Among authors: hayashi s. Viruses. 2022 Nov 8;14(11):2468. doi: 10.3390/v14112468. Viruses. 2022. PMID: 36366568 Free PMC article.
Drug Discovery Study Aimed at a Functional Cure for HBV.
Watanabe T, Hayashi S, Tanaka Y. Watanabe T, et al. Among authors: hayashi s. Viruses. 2022 Jun 26;14(7):1393. doi: 10.3390/v14071393. Viruses. 2022. PMID: 35891374 Free PMC article. Review.
Characterization of novel entecavir resistance mutations.
Hayashi S, Murakami S, Omagari K, Matsui T, Iio E, Isogawa M, Watanabe T, Karino Y, Tanaka Y. Hayashi S, et al. J Hepatol. 2015 Sep;63(3):546-53. doi: 10.1016/j.jhep.2015.03.020. Epub 2015 Mar 25. J Hepatol. 2015. PMID: 25817219
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
Higashi-Kuwata N, Hayashi S, Kumamoto H, Ogata-Aoki H, Das D, Venzon D, Hattori SI, Bulut H, Hashimoto M, Otagiri M, Takamune N, Kishimoto N, Davis DA, Misumi S, Kakuni M, Tanaka Y, Mitsuya H. Higashi-Kuwata N, et al. Among authors: hayashi s. J Hepatol. 2021 May;74(5):1075-1086. doi: 10.1016/j.jhep.2020.12.006. Epub 2020 Dec 15. J Hepatol. 2021. PMID: 33333207 Free PMC article.
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.
Tokunaga T, Tateyama M, Tanaka K, Narahara S, Inada H, Kurano S, Hayashi S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: hayashi s. Hepatol Res. 2022 Jan;52(1):105-119. doi: 10.1111/hepr.13720. Epub 2021 Oct 22. Hepatol Res. 2022. PMID: 34626450
Synthesis of novel entecavir analogues having 4'-cyano-6''-fluoromethylenecyclopentene skeletons as an aglycone moiety as highly potent and long-acting anti-hepatitis B virus agent.
Kumamoto H, Higashi-Kuwata N, Hayashi S, Das D, Bulut H, Tokuda R, Imoto S, Onitsuka K, Honda Y, Odanaka Y, Shimbara-Matsubayashi S, Haraguchi K, Tanaka Y, Mitsuya H. Kumamoto H, et al. Among authors: hayashi s. RSC Adv. 2023 May 31;13(23):15999-16011. doi: 10.1039/d3ra01750h. eCollection 2023 May 22. RSC Adv. 2023. PMID: 37265996 Free PMC article.
28 results